BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11585027)

  • 1. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?
    Jones R; Twelves C
    Expert Opin Pharmacother; 2001 Sep; 2(9):1495-505. PubMed ID: 11585027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
    Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
    Hoff PM; Lassere Y; Pazdur R
    Drugs; 1999; 58 Suppl 3():77-83. PubMed ID: 10711845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral fluorouracil prodrugs.
    Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Answering patients' needs: oral alternatives to intravenous therapy.
    Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
    Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
    Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
    Lima AP; del Giglio A
    Eur J Cancer Care (Engl); 2005 May; 14(2):151-4. PubMed ID: 15842464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral chemotherapy agents.
    Royce ME; Hoff PM; Pazdur R
    Curr Oncol Rep; 2000 Jan; 2(1):31-7. PubMed ID: 11122822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
    Kim DJ; Kim TI; Suh JH; Cho YS; Shin SK; Kang JK; Kim NK; Kim WH
    Yonsei Med J; 2003 Aug; 44(4):665-75. PubMed ID: 12950123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral tegafur/uracil.
    Wellington K; Goa KL
    Drugs Aging; 2001; 18(12):935-48; discussion 949-50. PubMed ID: 11888348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uracil-tegafur in gastric carcinoma: a comprehensive review.
    Takiuchi H; Ajani JA
    J Clin Oncol; 1998 Aug; 16(8):2877-85. PubMed ID: 9704742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
    Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.